Seminars in Hematology
Volume 41, Issue 1 , Pages 75-82 , January 2004

Von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience

  • Johanna A Kremer Hovinga

      Affiliations

    • Central Hematology Laboratory, Inselspital, University of Bern, Bern, Switzerland
    • ,
  • Jan-Dirk Studt

      Affiliations

    • Central Hematology Laboratory, Inselspital, University of Bern, Bern, Switzerland
    • ,
  • Lorenzo Alberio

      Affiliations

    • Central Hematology Laboratory, Inselspital, University of Bern, Bern, Switzerland
    • ,
  • Bernhard Lämmle

      Affiliations

    • Central Hematology Laboratory, Inselspital, University of Bern, Bern, Switzerland
    • Corresponding Author InformationAddress correspondence to Bernhard Lämmle, MD, Central Hematology Laboratory, Inselspital, University Hospital, CH-3010, Bern, Switzerland

References 

  1. Torok TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States—Analysis of national mortality data, 1968–1991. Am J Hematol. 1995;50:84–90
  2. Rock GA. Management of thrombotic thrombocytopenic purpura. Br J Haematol. 2000;109:496–507
  3. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries (A hitherto undescribed disease). Proc NY Pathol Soc. 1924;24:21–24
  4. Singer K, Bornstein F, Wiles A. Thrombotic thrombocytopenic purpura. Blood. 1947;2:542–544
  5. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600
  6. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, et al.  Unusually large plasma factor VIII (von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura). N Engl J Med. 1982;307:1432–1435
  7. Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest. 1991;88:774–782
  8. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223–4234
  9. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996;87:4235–4244
  10. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097–3103
  11. Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood. 1998;91:2839–2846
  12. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al.  Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578–1584
  13. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585–1594
  14. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98:1662–1666
  15. Gerritsen HE, Robles R, Lämmle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001;98:1654–1661
  16. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059–41063
  17. Levy GG, Nichols WC, Lian EC, Foroud T, McClintock JN, McGee BM, et al.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488–494
  18. Soejima K, Mimura N, Hirashima M, Maeda H, Hamamoto T, Nakagaki T, et al.  A novel human metalloprotease synthesized in the liver and secreted into the blood (Possibly, the von Willebrand factor-cleaving protease). J Biochem (Tokyo). 2001;130:475–480
  19. Plaimauer B, Zimmermann K, Volkel D, Antoine G, Kerschbaumer R, Jenab P, et al.  Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood. 2002;100:3626–3632
  20. Upshaw JD. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med. 1978;298:1350–1352
  21. Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on thrombopoiesis. I: A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood. 1960;16:943–957
  22. Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, et al.  Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA. 2002;99:11902–11907
  23. Schneppenheim R, Budde U, Oyen F, Angerhaus D, Aumann V, Drewke E, et al.  Von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood. 2003;101:1845–1850
  24. Antoine G, Zimmermann K, Plaimauer B, Grillowitzer M, Studt JD, Lämmle B, et al.  ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol. 2003;120:821–824
  25. Savasan S, Lee SK, Ginsburg D, Tsai HM. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. Blood. 2003;101:4449–4451
  26. Assink K, Schiphorst R, Allford S, Karpman D, Etzioni A, Brichard B, et al.  Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int. 2003;63:1995–1999
  27. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura (Report of 16 cases and review of the literature). Medicine (Baltimore). 1966;45:139–159
  28. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393–397
  29. Hénon P. Treatment of thrombotic thrombopenic purpura. Results of a multicenter randomized clinical study. Presse Med. 1991;20:1761–1767
  30. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991;325:398–403
  31. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood. 2000;96:1223–1229
  32. Allford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol. 2003;120:556–573
  33. Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. Hämolytisch-urämische Syndrome (Bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen Anämien). Schweiz Med Wochenschr. 1955;85:905–909
  34. Dundas S, Murphy J, Soutar RL, Jones GA, Hutchinson SJ, Todd WT. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet. 1999;354:1327–1330
  35. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001;60:831–846
  36. Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, et al.  ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (relation to presenting features and clinical outcomes in a prospective cohort of 142 patients). Blood. 2003;102:60–68
  37. Bianchi V, Robles R, Alberio L, Furlan M, Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders (A severely deficient activity is specific for thrombotic thrombocytopenic purpura). Blood. 2002;100:710–713
  38. Kinoshita S, Yoshioka A, Park YD, Ishizashi H, Konno M, Funato M, et al.  Upshaw-Schulman syndrome revisited (A concept of congenital thrombotic thrombocytopenic purpura). Int J Hematol. 2001;74:101–108
  39. Studt JD, Kremer Hovinga JA, Alberio L, Bianchi V, Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies (Diagnostic experience 2001/2002 of a single research laboratory). Swiss Med Wkly. 2003;133:325–332
  40. Studt JD, Böhm M, Budde U, Girma JP, Varadi K, Lämmle B. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma (A multicenter comparison of different assay methods). J Thromb Haemost. 2003;1:1882–1887
  41. Cantrell JE, Phillips TM, Schein PS. Carcinoma-associated hemolytic-uremic syndrome (A complication of mitomycin C chemotherapy). J Clin Oncol. 1985;3:723–734
  42. Gordon LI, Kwaan HC. Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient. Semin Thromb Hemost. 1999;25:217–221
  43. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2001;8:286–293
  44. van der Plas RM, Schiphorst ME, Huizinga EG, Hene RJ, Verdonck LF, Sixma JJ, et al.  von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood. 1999;93:3798–3802
  45. Tsai HM, Chandler WL, Sarode R, Hoffman R, Jelacic S, Habeeb RL, et al.  von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res. 2001;49:653–659
  46. Mori Y, Wada H, Gabazza EC, Minami N, Nobori T, Shiku H, et al.  Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion. 2002;42:572–580
  47. Elliott MA, Nichols WL, Plumhoff EA, Ansell SM, Dispenzieri A, Gastineau DA, et al.  Posttransplantation thrombotic thrombocytopenic purpura (A single-center experience and a contemporary review). Mayo Clin Proc. 2003;78:421–430
  48. Hunt BJ, Lämmle B, Nevard CH, Haycock GB, Furlan M. von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost. 2001;85:975–978
  49. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies (A study of 111 cases). Blood. 2001;98:1765–1772
  50. Veyradier A, Obert B, Haddad E, Cloarec S, Nivet H, Foulard M, et al.  Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome. J Pediatr. 2003;142:310–317
  51. Remuzzi G, Galbusera M, Noris M, Canciani MT, Daina E, Bresin E, et al.  von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood. 2002;100:778–785
  52. Remuzzi G. Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No. J Thromb Haemost. 2003;1:632–634
  53. Tsai HM. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost. 2003;1:625–631
  54. Loof AH, van Vliet HH, Kappers-Klunne MC. Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura. Br J Haematol. 2001;112:1087–1088
  55. Moore JC, Hayward CP, Warkentin TE, Kelton JG. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood. 2001;98:1842–1846
  56. Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome (The role of von Willebrand factor-cleaving protease). Best Pract Res Clin Haematol. 2001;14:437–454
  57. Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol. 1994;88:816–825
  58. Schultz DR, Arnold PI, Jy W, Valant PA, Gruber J, Ahn YS, et al.  Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders (Identification of an 85 kD form of CD36 as a target antigen). Br J Haematol. 1998;103:849–857
  59. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, et al.  ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100:4033–4039
  60. Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med. 1995;122:569–572
  61. Kappers-Klunne MC, van der Meulen JH, Holdrinet RS, van der Meer J, Wijermans PW, Brand A. Thrombotic thrombocytopenic purpura in 13 Dutch centres (Treatment and longterm follow-up). Ned Tijdschr Geneeskd. 1997;141:1192–1196
  62. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med. 2003;138:105–108
  63. Scheiflinger F, Knoebl P, Trattner B, Plaimauer B, Mohr G, Dockal M, et al.  Non-neutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura (TTP). Blood. 2003; DOI 10.1182/blood-2003-05-1616
  64. George JN, Sadler JE, Lämmle B. Platelets (Thrombotic thrombocytopenic purpura). Hematology (Am Soc Hematol Educ Program). 2002;315–334

☆ Supported by a grant from the Swiss National Foundation for Scientific Research (32-66756.01).

PII: S0037-1963(03)00281-6

doi: 10.1053/j.seminhematol.2003.10.008

Seminars in Hematology
Volume 41, Issue 1 , Pages 75-82 , January 2004

Article Tools